- In April 2024, Neoteryx LLC, a U.S.-based microsampling innovator, expanded its Mitra microsampling device production capacity to meet growing demand from diagnostic labs and decentralized testing programs across North America. This scale-up reflects the rising preference for volumetric absorptive microsampling in chronic disease monitoring and remote patient care, reinforcing Neoteryx’s position in the capillary blood collection market
- In March 2024, Quest Diagnostics announced the integration of remote capillary blood collection devices into its home testing kits, aimed at enhancing accessibility and convenience for patients managing conditions such as diabetes and thyroid disorders. This move aligns with the growing demand for self-collection and mail-in lab testing services across the U.S., particularly post-pandemic
- In February 2024, BD (Becton, Dickinson and Company) launched a next-generation capillary blood collection system designed to improve ease of use, reduce hemolysis rates, and enhance sample integrity. This innovation supports BD’s focus on optimizing pre-analytical workflows and addresses increasing requirements from clinical labs for high-quality microsamples
- In January 2024, Drawbridge Health, a U.S.-based medtech firm, announced strategic partnerships with Canadian diagnostic networks to distribute its OneDraw blood collection device, which enables simplified blood sample collection at home. This partnership marks a major step toward expanding decentralized diagnostic capabilities in North America, particularly for routine biomarker and metabolic testing
- In December 2023, Tasso, Inc. received additional FDA clearance for its Tasso+ blood collection device, enhancing its applicability for remote clinical trials and personalized medicine initiatives across the U.S. and Canada. The clearance facilitates wider adoption of self-collection technologies and strengthens Tasso’s contribution to home-based healthcare innovation in the region
